Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary

Conditions:Ovarian Cancer, Cancer
Therapuetic Areas:Oncology
Age Range:21 - Any
Start Date:January 2007

Use our guide to learn which trials are right for you!

Microvascular Perfusion Sonographic Imaging to Detect Early Stage Ovarian Cancer

RATIONALE: New diagnostic procedures, such as contrast-enhanced ultrasonography, may be an
effective method of finding ovarian cancer.

PURPOSE: This clinical trial is studying how well contrast-enhanced ultrasonography works in
diagnosing early-stage ovarian cancer in patients with an adnexal mass undergoing surgery to
remove the ovary.


- Determine whether use of a contrast agent improves the images of the ovaries during

OUTLINE: This is a multicenter study.

Patients may undergo baseline transabdominal or transvaginal ultrasonography, if not already
done. Patients then undergo contrast-enhanced transabdominal or transvaginal ultrasonography
using perflutren lipid microspheres (Definity®) IV.

Pathology reports from tissue collected during subsequent oophorectomy is analyzed and
compared with ultrasonography findings.


- Diagnosis of adnexal mass

- Scheduled to undergo surgical oophorectomy


- Not pregnant or nursing

- Negative pregnancy test

- No known respiratory failure as manifested by signs and symptoms of carbon dioxide
retention or hypoxemia

- No pulmonary vasculitis

- No known history of severe emphysema

- No known history of pulmonary emboli

- No other condition that causes pulmonary hypertension due to compromised pulmonary
arterial vasculature

- No known history of severe pulmonary hypertension (i.e., systolic pulmonary artery
pressures > 90 mm Hg)

- No known history of congenital heart defect that creates a bidirectional or
right-to-left shunt

- No worsening or clinically unstable congestive heart failure

- No known acute myocardial infarction or acute coronary syndromes

- No known serious ventricular arrhythmias

- Not at high risk for arrhythmia due to prolongation of the QT interval

- No known or suspected hypersensitivity to blood, blood products, or albumin

- No known hypersensitivity to perflutren

- No known or suspected hypersensitivity to octafluoropropane or any other ingredients
of perflutren lipid microspheres (Definity®)

- No mental status problems, illiteracy, or other circumstance that would preclude
giving informed consent


- See Disease Characteristics
We found this trial at
2220 Pierce Ave
Nashville, Tennessee 37232
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
Nashville, TN
Click here to add this to my saved trials
324 Cool Springs Blvd
Nashville, Tennessee 37067
(877) 936-8422
Vanderbilt-Ingram Cancer Center - Cool Springs Vanderbilt-Ingram Cancer Center Cool Springs is a medical oncology...
Nashville, TN
Click here to add this to my saved trials
2107 Edward Curd Lane
Nashville, Tennessee 37067
Vanderbilt-Ingram Cancer Center at Franklin The Vanderbilt-Ingram Cancer Center at Franklin is a free-standing radiation...
Nashville, TN
Click here to add this to my saved trials